XERS · Xeris Biopharma Holdings, Inc.
$10.21
+0.10% last session
End-of-day data · close of 2026-10-26
Market cap
$2B
Enterprise value
$2B
Trailing P/E
—
Forward P/E
51.9
Dividend yield
0.0%
Beta
0.84
Avg volume
2M
Employees
0K
Daily Change %
0.10%
5 Days Change
-5.99%
10 Days Change
-0.97%
30 Days Change
12.20%
60 Days Change
20.40%
Month to Day Change
10.38%
Year to Day Change
30.06%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — XERS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-06
Latest call per bank · past 12 months
Barclays
Overweight$14.00
+37.1% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-06 | Barclays | Maintains | Overweight | $12.00 → $14.00 |
| 2026-09-10 | Leerink Partners | Maintains | Outperform | $12.00 → $16.00 |
| 2026-08-20 | Barclays | Maintains | Overweight | $9.00 → $12.00 |
| 2026-03-02 | HC Wainwright & Co. | Reiterates | Buy | $10.00 |
| 2026-01-09 | HC Wainwright & Co. | Reiterates | Buy | $10.00 |
| 2025-12-09 | Barclays | Initiates | Overweight | $0.00 → $9.00 |
| 2025-11-07 | Oppenheimer | Maintains | Outperform | $18.00 |
| 2025-11-07 | HC Wainwright & Co. | Maintains | Buy | $10.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 54 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 11.6% above the 50-day MA ($9.15).
- bullish: Price vs 200-day MA: Trading 37.2% above the 200-day MA ($7.44).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bearish: MACD (12,26,9): MACD histogram is negative (-0.05) — short-term momentum is fading.
- neutral: 52-week range: Price sits between the 52-week low ($5.29) and high ($11.13).
XERS Price Chart
Loading chart for XERS…
Fundamentals
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase 3 clinical trial for the treatment of hypothyroidism. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
More in Drug Manufacturers - Specialty & Generic
TAK
Takeda Pharmaceutical Company L
$65B 31.1% YTD
TEVA
Teva Pharmaceutical Industries
$47B 28.0% YTD
HLN
Haleon plc
$45B 2.9% YTD
ZTS
Zoetis Inc.
$33B -34.6% YTD
UTHR
United Therapeutics Corporation
$25B 21.7% YTD
VTRS
Viatris Inc.
$21B 50.4% YTD
NBIX
Neurocrine Biosciences, Inc.
$15B 2.9% YTD
ELAN
Elanco Animal Health Incorporat
$11B 1.5% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.